COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

clinical-trials-Schizophrenia

Clinical Trials – Treatment for Patients with Schizophrenia.

Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia.

clinical-trials

Clinical Trials – Phase 3 of Investigational Vaccine Against RSV.

Pfizer announced the initiation of RENOIR, a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its RSV vaccine.

GM1-gangliosidosis

Phase I/II trial of gene therapy for GM1 gangliosidosis.

GM1 gangliosidosis is an autosomal recessive disease that develops due to mutations in the ?-galactosidase gene (GLB1) gene.

booster-shot-trial

Covid-19 – Booster dose trial in autoimmune disease patients.

The trial will mainly assess antibody response four weeks following the additional dose versus after the original vaccine shots.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.